Abstract
Despite its potent in vitro anti-cancer activity, the vitamin E extract tocotrienol has its therapeutic potential hampered by its poor bioavailability and by its inability to reach tumors in a specific way after intravenous administration. One possibility to overcome this issue would be to entrap tocotrienol within vesicles bearing transferrin, whose receptors are present in abundance on many cancer cell types. In this study, we demonstrated that the systemic administration of tocotrienol entrapped within transferrin-bearing vesicles led to tumor suppression of 20% of A431 epidermoid carcinoma tumors and 50% of B16-F10 melanoma tumors at the end of the treatment. The survival of animals treated with these vesicles was improved by more than 20 days in comparison with the controls, for the two cancer models tested. Animals did not show any secondary effects following administration of the treatment. The entrapment of tocotrienol within transferrin-bearing vesicles is therefore a promising therapeutic strategy, which could result in tumor suppression after systemic administration of this delivery system.
Keywords: Cancer therapy, delivery system, in vivo, tocotrienol, transferrin, tumor targeting.
Pharmaceutical Nanotechnology
Title:Anti-Cancer Efficacy of Intravenously Administered Tumor- Targeted Vesicles Entrapping Tocotrienol
Volume: 2 Issue: 4
Author(s): Ju Yen Fu and Christine Dufes
Affiliation:
Keywords: Cancer therapy, delivery system, in vivo, tocotrienol, transferrin, tumor targeting.
Abstract: Despite its potent in vitro anti-cancer activity, the vitamin E extract tocotrienol has its therapeutic potential hampered by its poor bioavailability and by its inability to reach tumors in a specific way after intravenous administration. One possibility to overcome this issue would be to entrap tocotrienol within vesicles bearing transferrin, whose receptors are present in abundance on many cancer cell types. In this study, we demonstrated that the systemic administration of tocotrienol entrapped within transferrin-bearing vesicles led to tumor suppression of 20% of A431 epidermoid carcinoma tumors and 50% of B16-F10 melanoma tumors at the end of the treatment. The survival of animals treated with these vesicles was improved by more than 20 days in comparison with the controls, for the two cancer models tested. Animals did not show any secondary effects following administration of the treatment. The entrapment of tocotrienol within transferrin-bearing vesicles is therefore a promising therapeutic strategy, which could result in tumor suppression after systemic administration of this delivery system.
Export Options
About this article
Cite this article as:
Fu Yen Ju and Dufes Christine, Anti-Cancer Efficacy of Intravenously Administered Tumor- Targeted Vesicles Entrapping Tocotrienol, Pharmaceutical Nanotechnology 2014; 2 (4) . https://dx.doi.org/10.2174/2211738503666150119231232
DOI https://dx.doi.org/10.2174/2211738503666150119231232 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hydroxychloroquine (HCQ) and its Synthetic Precursors: A Review
Mini-Reviews in Organic Chemistry Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma
Anti-Cancer Agents in Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Synthesis and Antitumor Evaluation of Novel N-substituted Norcantharidin Imidazolium Derivatives
Current Organic Synthesis Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy Preparation and <I>In Vitro/Vivo</I> Evaluation of Folate-conjugated Pluronic F87-PLGA/TPGS Mixed Nanoparticles for Targeted Drug Delivery
Current Drug Delivery The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued)